Treating Uncommon EGFR Mutations in Patients with NSCLC

Expert oncologists reflect on the state of molecular testing in non–small cell lung cancer and how it informs the management of patients with uncommon EGFR mutations.

EP. 1: Evolving Field of Molecular Testing in Non–Small Cell Lung Cancer

June 30th 2023

Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.

EP. 2: NSCLC: Selecting a Molecular Testing Assay and Interpreting Results

July 7th 2023

Shared perspective on the armamentarium of molecular testing assays in non–small cell lung cancer and how results can be best interpreted when selecting treatment.

EP. 3: Overcoming Barriers to Molecular Testing in NSCLC With Multidisciplinary Care

July 7th 2023

A brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.

EP. 4: Refining EGFR Classifications and Impact on Treatment for NSCLC

July 14th 2023

Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.

EP. 5: Treatment Options for Patients with Uncommon EGFR Mutations in NSCLC

July 14th 2023

Focused discussion on uncommon EGFR mutations in non–small cell lung cancer and concurrent treatment options in this setting.

EP. 6: Uncommon EGFR Mutations in NSCLC: Real-World Selection and Use of Novel Agents

July 21st 2023

Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, reflect on their experience managing real-world patients with uncommon EGFR mutations in non–small cell lung cancer.

EP. 7: Uncommon EGFR Mutations in NSCLC: Future Directions in Care

July 21st 2023

Closing out their discussion on uncommon EGFR mutations in non–small cell lung cancer, Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, consider how the treatment paradigm will continue to evolve.